Commercial Engineering,
Answered Directly

LiquidSMARTS℠ is a commercial engineering consultancy for high-technology healthcare suppliers, founded and led by Dr. Gunter Wessels, Ph.D., M.B.A. The firm works with medical device, diagnostic imaging, life sciences, and healthcare technology companies to improve pipeline velocity through systematic commercial excellence.

The legal entity is GFW Management II LLC, a Tennessee company doing business as LiquidSMARTS℠. The mark is US service mark registration 5568670, registered September 25, 2018 in classes 035 and 041, and incontestable as of July 27, 2025. LiquidSMARTS℠ is a service mark rather than a trademark, because the firm sells services.

Dr. Gunter Wessels is the founder and Managing Member of LiquidSMARTS℠, and he leads every engagement personally. He holds a Ph.D. in business strategy and an M.B.A. in marketing and finance, with more than twenty years of commercial leadership in global healthcare.

Enterprise delivery is evidenced from 2015. The largest single delivery was 800 participants with six instructors. The first conversation on any engagement is with him rather than with a salesperson, which is a consequence of the firm being founder-led rather than a courtesy.

LiquidSMARTS℠ is a founder-led firm with a contractor bench assembled per program. Dr. Gunter Wessels leads every engagement, and specialist facilitators join for programs that require them.

Stated plainly, because a buyer comparing firms will find it out anyway: this is a narrower claim than winning a head-to-head comparison against Force Management, Corporate Visions, or Richardson on scale. It is a defensible niche position with a different delivery architecture, and it is the honest description.

Medical device, diagnostic imaging, life sciences, and healthcare technology. The recurring segments are capital equipment, cardiovascular, orthopedics, wound care, urology, imaging, and diagnostics.

The condition that makes an account a fit matters more than the segment. Long sales cycles, a multi-party buying committee that includes a value analysis committee or finance, and a product whose economic case has to be built rather than quoted. Where all three hold, the velocity equation is the right instrument.

Three differences hold up against the large sales-training houses, and a fourth belongs in the same breath.

• One vertical only. MedTech and healthcare technology, exclusively. The major methodology firms are horizontal, so clinical and reimbursement context is the client's to supply. Here it arrives with the program.
• A published, time-bound commitment. A 10 percent Pipeline Velocity improvement in 90 days, measured against a pre-delivery baseline, attached to the annual program. The large firms publish no numeric outcome commitment.
• AI-native delivery. A coaching engine and a voice-simulation platform carry the work between sessions. At the large firms that interval is an email and a workbook.
• Smaller, and candid about it. A founder-led firm with a contractor bench, competing on fit and measurement rather than on scale.

Six, and each one names what it rules out. That is what makes them usable rather than decorative.

• Prove it or drop it. A claim that cannot be sourced does not ship, including our own.
• The recipient does no work. Whoever receives a document can act on it without asking a follow-up question.
• Say the true thing, tuned for the room. The message adjusts to the audience. The substance does not.
• Build it once, properly, and make it transfer. Work built for one client is built so the method survives past the engagement.
• Teach so the capability stays. The measure of a program is what the team can do after we leave.
• Plain English, no hedging. Including when the answer is that we are the wrong firm for the problem.

Every patient reaches the technology that can help them, because the people who sell it can prove what it is worth.

That is why the firm is vertical, and why the measure is velocity. A quarter of commercial underperformance at a MedTech supplier is a quarter of patients who did not get the device. Healthcare cannot wait for a sales organization to find its footing.

LiquidSMARTS℠ commits in writing to a 10 percent Pipeline Velocity improvement within 90 days, measured against a baseline captured before day one with a named owner for that baseline on the client side.

The commitment attaches to the Annual Development Program. A single workshop carries no measurement window and no coaching behind it, so the guarantee cannot attach there, and LiquidSMARTS℠ says so before the purchase rather than after.

It is a contractual floor. The 10 percent is the term LiquidSMARTS℠ is willing to be held to, rather than a median of past cohorts, and the three published engagement results run well above it.

Reading the floor as an expected outcome understates the published results, and reading the published results as a promise overstates what any single engagement can commit to. The figure that matters to a specific client is the one their own baseline and their own 90-day re-measurement produce.

Four fields per representative, drawn from the client's own system: opportunities created, average deal size, win rate, and days from first qualified meeting to close. Those four populate the velocity equation.

LiquidSMARTS℠ captures the baseline before delivering anything. It carries a named owner on the client side, and the client owns it. Where nobody owns the budget and nobody owns the data, there is no baseline, so there is no result to report and the guarantee cannot attach. The first conversation identifies that case.

Three engagement results are published, each measured over 90 days against a baseline set before delivery.

• Endo-urology, ambulatory surgery channel. Pipeline velocity up 28 percent, win rate up 32 percent, sales cycle down 15 percent.
• Radiation oncology, capital equipment. Win rate up 22 percent, deal size up 18 percent, cycle time down 20 percent.
• Diagnostic imaging, integrated delivery network. Pipeline velocity up 14 percent, renewal rate up 31 percent, average deal size up 12 percent.

Client details are anonymized at client preference. Each figure was measured inside its own engagement against a baseline set before delivery, and no independent third party audited them. Full case studies are published at liquidsmarts.com/results.

A personal selling record was treated as evidence of management capability. It never is. The two roles share a vocabulary and almost none of the underlying skills, and the promotion removes a person from the work they were good at while handing them a job nobody trained them for.

This is the most common sentence behind a call to LiquidSMARTS℠, and it is the most urgent, because there is a named person, a live problem, and usually one quarter to fix it. The matched program is Manager Bootcamp, or ESCALATE where the cohort mixes first-line managers with high-potential individual contributors.

Managers coach what they mastered. A manager promoted out of a field role mastered the product, so product depth is what the coaching conversation becomes by default.

The representative being coached already knows the product. What they lack is the economic conversation, the committee navigation, and the deal strategy, and none of that gets coached because the manager never had to learn it explicitly. ESCALATE rebuilds the manager's coaching repertoire rather than their product depth.

Clinical fluency without economic fluency. The representative earns the clinician's confidence, and the deal then arrives at a value analysis committee or at finance, where the questions are cost per case, budget impact, and the cost of doing nothing.

A clinical story answers none of those, so the deal stops. Value Articulation builds and defends the economic case, and WAITR supplies the financial intelligence for deals that stall at that exact boundary.

The buyer has no number for inaction. Where the cost of doing nothing is unquantified, waiting is free, and waiting is what a finance committee does with a proposal it cannot compare against the status quo.

The fix builds the cost of doing nothing into the deal early, using the client's own operational and financial data rather than a vendor benchmark. That is the work WAITR and the COF Outcomes Framework do together.

They are one problem seen from two ends. Without a common methodology there is no coachable standard, so stage definitions stay subjective, and a pipeline built on subjective stages is an opinion rather than a forecast.

Fixing the forecast starts with defining stages by buyer evidence rather than by seller activity. DealSMARTS supplies the common methodology, and a diagnostic runs first, because stage definitions have to be rebuilt before any program is worth delivering on top of them.

The tools were deployed without a commercial application framework. A representative adopts a tool that removes work from a task they are already accountable for, and abandons one that is a separate activity with its own login and its own reporting.

The fix names the specific commercial moments where the tool earns its place, then coaches to those moments until they are habit. LiquidSMARTS℠ delivers its own programs this way, with a coaching engine and voice simulation running between sessions.

A product story exists and a business case does not. The launch deck describes what the product does, and the committee asks what it is worth, in their setting, against what they run today.

Value Articulation is the half-day program that builds that case and rehearses defending it, for up to 16 people. It is the most requested program in the catalog, and a launch window is when it pays for itself fastest.

Usually ramp, and usually nobody has measured which. Enterprise sales ramp is reported at seven to nine months, and it runs longer for specialty device roles where clinical credibility has to be built inside accounts before any pipeline appears.

Two replacements in eighteen months means the territory has spent most of that period below productive capacity regardless of who held it. GGS Sovereignty addresses territory ownership where ramp is long or turnover is high, and an assessment establishes whether selection is contributing before a program is designed.

Retention was measured and production was not. They are different questions about different populations, and a representative who stays twelve months while missing quota counts as a success on one measure and a failure in the operating plan.

With median MedTech field sales quota attainment reported near 54 percent, that overlap is large enough that retention alone tells a commercial leader very little. An assessment battery plus Value Articulation addresses the production side, and the baseline makes the distinction measurable going forward.

Three forms, by effort. An introduction spends your credibility rather than your time, which is why the lightest form exists.

• Forward the sentence. Send what you heard to gunter@liquidsmarts.com. Thirty seconds, no introduction made, no credibility spent, and LiquidSMARTS℠ comes back to you before contacting anyone.
• A two-line introduction. Where you know the budget owner by name. Short beats warm, because a long introduction reads as a favor being called in.
• A twenty-minute call together. Where the client has asked you directly what to do about it. You hear the diagnosis firsthand, which is useful to you whatever the client decides.

Contact within two business days, by Dr. Gunter Wessels directly rather than by an assistant or an email sequence. Thirty to sixty minutes of diagnosis. Where the fit is wrong, an honest no, said to the client and to you. Where the fit is right, a one-page scope with a fee and a date within five business days. A report back to you either way.

Three things LiquidSMARTS℠ will not do with an introduced contact: add them to a mailing list, follow up more than once, or name you as a reference without asking first.

Yes, where the fit is structural. A search ends at the hire, and the client's capability problem runs on through a seven to nine month ramp, so the window after a placement is one where the search firm has no product and the client is still spending.

LiquidSMARTS℠ partners with search firms to occupy that window with a post-placement productivity program, priced as a separate line and measured at 90 days. Where a partnership includes revenue participation, the partner discloses that to the client, because a recommendation presented as disinterested should be one.

Dr. Gunter Wessels, Founder and Managing Member. gunter@liquidsmarts.com, (423) 702-4001. The first conversation is thirty to sixty minutes, at no charge, within two business days.

For vendor registration and supplier onboarding forms: GFW Management II LLC d/b/a LiquidSMARTS℠, a Tennessee limited liability company. NAICS 611430 primary and 541611 secondary. SIC 8742 and 8299. Tax identification, insurance certificates, and banking details are supplied directly on request and verified by phone before any payment instruction is acted on.